Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...
After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said that results from the MANDARA Phase III trial showed the company's FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...
Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA(benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FASENRA PEN contains the active ingredient benralizumab. FASENRA PEN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback